BackXilio Therapeutics Overview

Xilio Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for XLO.

Quarterly EBIT

-$14.11M
1.88% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$25.96M
54.42% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)